Vision-Ease Lens and the Skin Cancer Foundation promote eye protection

Article

With sun safety a growing concern and the sun season in full swing, Vision-Ease Lens (VEL) and the Skin Cancer Foundation (SCF) are working together to educate consumers about the importance of sun protection for the eyes.

Key Points

Ramsey, MN-With sun safety a growing concern and the sun season in full swing, Vision-Ease Lens (VEL) and the Skin Cancer Foundation (SCF) are working together to educate consumers about the importance of sun protection for the eyes.

The partnership includes VEL as the official sponsor of SCF's first-ever online eye-safety educational campaign to raise awareness of the importance of protecting eyes from harmful ultraviolet and high-energy visible light.

The campaign's educational content, planned to reach thousands of consumers, stresses the importance of broad-spectrum sun protection, especially around the eyes, to help protect against a wide range of sun-related damage.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.